Citing recommendations and guidelines from worldwide government agencies and organizations, researchers believe that the consensus supports the safety of vaccinations for patients with rheumatoid arthritis who are undergoing treatment with disease-modifying antirheumatic drugs.
Research has shown that Disease Activity Scores are inflated as a result of pain reports that do not reflect actual disease activity in rheumatoid arthritis.
Investigators found evidence that both aerobic and resistance training lowers insulin resistance, but further studies are needed to determine the specific effects in patients with rheumatoid arthritis.
Data suggest that patients in remission with baricitinib 4 mg daily dose who have taken this medication for at least 1 year may be able to attempt baricitinib dose-tapering while continuing their methotrexate regimen.
Researchers found that data showed that a high percentage of black patients with rheumatoid arthritis had a cardiovascular disease factor and that about half had specific rheumatoid arthritis risk factors, such as joint erosions, elevated inflammatory markers, extra-articular disease, and body mass indexes below 20, which requires effective intervention.
Researchers created a model for general practitioners to use for patients who are atypical for detection of inflammatory arthritis, which included difficulty forming a fist, joint swelling (self-reported), between 1 and 3 painful joints, stiffness <1 hour in the morning, fewer than 6 weeks of symptom duration, male gender, and age of at least 60 years.
Researchers posit that improvement of health related quality of life should be an objectives of treatment of early arthritis and early inflammatory back pain, but their finding is that disease only explains part of the assessment of quality of life.
Researchers found data indicative of the responsiveness of combined scores for inflammation, which could be improved with normalized or weighted summation of the Outcome Measures in Rheumatology RA MRI Scoring system pathologies, rather than unweighted summation.
Investigators found that while in vivo and in vitro preclinical trials of toreforant reduced IL-17 production and arthritis disease severity, phase 2 study data showed low levels of efficacy in patients with RA.
![Cardiovascular changes associated with AS may begin early in the disease process. Thus, assessment of cardiovascular risk should be routine for all patients affected with this disease. Preventing CVD or cardiovascular death depends on early identification and effective management of traditional cardiovascular risk factors such as hypertension or hypercholesterolemia. Despite their importance, screening and treatment of CVD risk factors in patients with rheumatic diseases are often suboptimal. One reason for suboptimal management may be confusion over who is responsible for monitoring cardiovascular risk in patients with AS.[14] The lack of disease-specific guidelines for risk assessment is another concern. Ensuring patients with AS are screened and managed appropriately for CVD will require collaboration between the rheumatologist or specialist nurse, the general practitioner, and the patient.[14]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/8heartmonitorvitalsignsts_1032652.jpg)
